uBriGene and Cellinfinity BIO Partner to Advance In Vivo CAR-T Therapies

The strategic alliance aims to accelerate the development of next-generation cell therapies.

Mar. 30, 2026 at 12:37pm

Got story updates? Submit your updates here. ›

A highly textured, abstract painting in soft pastel colors featuring sweeping geometric shapes, concentric circles, and precise botanical spirals, conceptually representing the complex scientific forces and potential of in vivo cell engineering technologies.A strategic partnership aims to accelerate the development of innovative in vivo CAR-T therapies, a transformative approach to cancer treatment.Germantown Today

uBriGene Biosciences, a clinical-stage biopharmaceutical company, and Cellinfinity BIO, a leader in in vivo cell engineering, have announced a strategic partnership to advance the development of innovative in vivo CAR-T therapies. The collaboration will leverage the complementary expertise and technologies of both companies to accelerate the translation of novel cell-based treatments for cancer and other diseases.

Why it matters

This partnership represents a significant step forward in the field of in vivo CAR-T therapy, which has the potential to revolutionize cancer treatment by enabling more targeted and personalized approaches. The combination of uBriGene's drug development capabilities and Cellinfinity's in vivo cell engineering platform could lead to breakthroughs that improve patient outcomes and access to these transformative therapies.

The details

Under the terms of the agreement, the companies will jointly develop and commercialize in vivo CAR-T therapies, with uBriGene responsible for clinical development and regulatory activities, and Cellinfinity contributing its proprietary in vivo cell engineering technology. The partnership will initially focus on advancing uBriGene's lead CAR-T candidate, which targets a novel tumor antigen, through clinical trials.

  • The strategic partnership was announced on March 30, 2026.

The players

uBriGene Biosciences

A clinical-stage biopharmaceutical company focused on developing innovative cell-based therapies for cancer and other diseases.

Cellinfinity BIO

A leader in in vivo cell engineering, with proprietary technologies that enable the targeted modification of cells within the body.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to partner with Cellinfinity BIO to advance our in vivo CAR-T program and bring this promising technology to patients in need.”

— Dr. Emily Huang, CEO of uBriGene Biosciences

“This collaboration with uBriGene represents a significant opportunity to accelerate the development of transformative in vivo cell therapies and improve patient access to these innovative treatments.”

— Dr. Michael Li, CEO of Cellinfinity BIO

What’s next

The companies plan to initiate a Phase 1 clinical trial for uBriGene's lead in vivo CAR-T candidate by the end of 2026.

The takeaway

This strategic partnership between uBriGene and Cellinfinity BIO highlights the growing momentum in the field of in vivo cell engineering and the potential for these technologies to revolutionize cancer treatment by enabling more targeted and personalized therapies.